NFE2L2 and ovarian cancer: Following the observed inhibition of NRF2 and increase in ROS and downregulation of HER1 receptor expression and levels in ovarian cancer cells after their treatment with bexarotene and siRNAs, we anticipated that NRF2 knockdown with siRNA and/or treatment with bexarotene would cause a depletion of total cellular GSH.